{"filing":{"accession_number":"0001193125-26-286880","cik":"0001650648","ticker":"FDMT","company_name":"4D Molecular Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"d146057d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526286880/d146057d8k.htm"},"events":[{"id":14481,"run_id":12893,"accession_number":"0001193125-26-286880","anchor_item_number":"1.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"4D Molecular Therapeutics entered into a Loan and Security Agreement with Hercules Capital on June 24, 2026, establishing a new term loan facility of up to $200 million maturing June 1, 2031. The agreement includes specified interest rates, facility charges, covenants, and security interests.","company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":11937,"accession_number":"0001193125-26-286880","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"4D Molecular Therapeutics entered into a Loan and Security Agreement with Hercules Capital on June 24, 2026, creating a new direct financial obligation of up to $200 million in term loans with a maturity date of June 1, 2031. The disclosure details the loan structure, interest rates, facility charges, covenants, and security interests, which are hallmarks of a material debt issuance. This is a significant capital-raising event that would materially affect a reasonable investor's assessment of the company's financial obligations and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T12:06:45.918824+00:00","company_name":"","ticker":null,"filing_date":""},{"id":11938,"accession_number":"0001193125-26-286880","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Item 2.03 is filed and incorporates Item 1.01 by reference, indicating creation of a direct financial obligation. While the specific details are not provided in this excerpt, Item 2.03 filings typically disclose debt issuances, credit facilities, or other financial obligations. The incorporation of Item 1.01 (Business Combinations) suggests this may relate to acquisition financing or a material transaction-related obligation, making debt_issuance the most probable classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T12:06:45.918824+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11937,"accession_number":"0001193125-26-286880","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"4D Molecular Therapeutics entered into a Loan and Security Agreement with Hercules Capital on June 24, 2026, creating a new direct financial obligation of up to $200 million in term loans with a maturity date of June 1, 2031. The disclosure details the loan structure, interest rates, facility charges, covenants, and security interests, which are hallmarks of a material debt issuance. This is a significant capital-raising event that would materially affect a reasonable investor's assessment of the company's financial obligations and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T12:06:45.918824+00:00","company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","filing_date":"2026-06-29"},{"id":11938,"accession_number":"0001193125-26-286880","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Item 2.03 is filed and incorporates Item 1.01 by reference, indicating creation of a direct financial obligation. While the specific details are not provided in this excerpt, Item 2.03 filings typically disclose debt issuances, credit facilities, or other financial obligations. The incorporation of Item 1.01 (Business Combinations) suggests this may relate to acquisition financing or a material transaction-related obligation, making debt_issuance the most probable classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T12:06:45.918824+00:00","company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","filing_date":"2026-06-29"}]}